See more : National Aluminium Company Limited (NATIONALUM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Checkmate Pharmaceuticals, Inc. (CMPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Checkmate Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Instem plc (INS.L) Income Statement Analysis – Financial Results
- First Copper Technology Co., Ltd. (2009.TW) Income Statement Analysis – Financial Results
- Kuei Tien Cultural & Creative Entertainment (4806.TWO) Income Statement Analysis – Financial Results
- Rio Tinto Group (RTNTF) Income Statement Analysis – Financial Results
- BCE Inc. (BCEPF) Income Statement Analysis – Financial Results
Checkmate Pharmaceuticals, Inc. (CMPI)
About Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.82M | 26.72M | 24.25M | 18.17M |
| General & Administrative | 15.65M | 10.19M | 4.64M | 2.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.65M | 10.19M | 4.64M | 2.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Cost & Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Interest Income | 100.00K | 79.00K | 197.00K | 180.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 66.00K | 188.00K | 597.00K | 180.00K |
| EBITDA | -61.34M | -36.72M | -28.29M | -20.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.41M | -36.90M | -28.89M | -20.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00K | 597.00K | 180.00K |
| Income Before Tax | -61.41M | -36.91M | -28.29M | -20.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 0.00 | 0.00 |
| Net Income | -61.41M | -36.91M | -28.29M | -20.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.42 | -3.86 | -3.44 | -2.53 |
| EPS Diluted | -6.42 | -3.86 | -3.44 | -2.53 |
| Weighted Avg Shares Out | 9.56M | 9.56M | 8.22M | 8.22M |
| Weighted Avg Shares Out (Dil) | 9.56M | 9.56M | 8.22M | 8.22M |
Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress
Checkmate Pharmaceuticals to Present Data at the 2021 American Association for Cancer Research (AACR) Annual Meeting
U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team
Wall Street Breakfast: The Week Ahead
Checkmate Pharmaceuticals Begins IPO Process
U.S. IPO Weekly Recap: nCino Pops 195% In 8-IPO Week
Source: https://incomestatements.info
Category: Stock Reports